by Dan Roberts June 19, 2011 Introduction Since 2006, I have done my best to condense the high points of the previous year’s macular degeneration research into a single report that is concise and understandable for the layperson. I do so, because I understand first hand how important it is to be aware of everything [Read More]
Tag: CATT
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration
The CATT Research Group April 2011 In 2005, clinical trials established the efficacy of ranibizumab (Lucentis, Genentech) for the treatment of neovascular age-related macular degeneration (AMD), the leading cause of legal blindness in the United States. While awaiting approval for ranibizumab from the Food and Drug Administration, ophthalmologists began treating neovascular AMD with off-label use [Read More]
Summary of Research and Developments in Macular Degeneration: 2007-2008
Compiled and edited by Dan Roberts JUNE 2007 Omega-3 Proving to be Beneficial on Several Fronts Recent studies have shown that Omega-3 fatty acids and fish consumption may reduce the risks of age-related macular degeneration (AMD), Alzheimer’s disease, inflammation and depression. The Age-Related Eye Disease Study (AREDS) Research Group showed that dietary total Omega-3 and [Read More]